Osteoporosis: Is PEMF therapy the ONLY solution?
Globally, osteoporosis causes more then 8.9 million fractures per annum. To put this into perspective, every three seconds an osteoporotic fracture occurs. Osteoporosis is one of the most common conditions faced by the ageing population, it characterised by the significant loss of bone mass and bone deterioration. Fragile bones significantly increase the risk of fractures. Osteoporosis has led to huge economic and socioeconomic impacts both in developing and developed countries. One in three women and one in five men over the age of fifty are expected to suffer a fracture caused by weak bones. Musculoskeletal diseases cause pain, disability, a loss of independence and premature death.
Bone mass density continuously builds until around age thirty. At this point bones have reached the peak mass density and strength. In the subsequent years however the bone density decreases, especially in women, as hormones play a major role in promotion of bone formation and regulation of bone resorption. When oestrogen and testosterone levels drop (happens quickly in women due to the onset of menopause), the risk for osteoporosis is heightened. When the loss of bone density hits a certain threshold a patient has a significant increased risk of fracture.
This threshold can be reached at different ages and the bone density loss varies depending on several factors including but not limited too: gender, age, diet, ethnicity, family history, hormones, sex hormone binding globulin, vertigo, underweight, obesity, cardiovascular disease, chronic stress, depression, medication/drug use, sedentary lifestyle, environmental impacts, insulin resistance, blood sugar, oxidation, inflammation, Vitamin K, D and Calcium deficiencies.
“Osteoporosis is a MAJOR DEVELOPING HEALTH PROBLEM WORLDWIDE”.
Osteoporosis drugs are the most common treatment method. Although medication may stop further degradation of the bone, research shows little success rates in stimulation of osteoblast activity, bone formation and increased bone density. Osteoclasts and osteoblasts work together to break down and then rebuild bone cells. Bones should always be rejuvenated so they can stay strong and flexible. Furthermore osteoporosis drugs present with a range of side effects that may compromise the biological function of the elderly or sick.
Drugs for Osteoporosis are Not a Solution!
Substantial research and evidence is being accumulated in regards to the use of Pulsed Electromagnetic Field (PEMF) therapy in concurrence with osteoporosis.
It has PROVEN to be the only NONINVASIVE method capable of producing substantial therapeutic effects to bone diseased patients.
Several studies (both in vitro and vivo) have demonstrated that PEMF can stimulate and promote osteogenesis, stimulate osteoblast activity and enhance bone mineralization.
A study conduced in 2013 on pulsed electromagnetic field therapy showed improved bone microstructure in rats. The study concluded that PEMF has proven to be an effective noninvasive method in the treatment of a wide range of bone diseases. Their findings in the study demonstrated that 10-week use of PEMF remarkably attenuated the induced bone loss and deterioration of bone micro-architecture in rats by promoting overall gene expressions.
Another study conducted in 2012 demonstrated that PEMF could induce the proliferation and differentiation of osteoblasts. The study used cultured cells (MC3T3-E1 osteoblasts derived from a mouse) and exposed them to PEMF for 30 minutes per day for 2 days. The study was also done in conjunction with dexamethasone which is a glucocorticoid known to induce osteoporosis via the medication. The results of the study showed that PEMF treated osteoblasts showed a significant increase in proliferation and differentiation. The dexamethasone significantly decreased the proliferation and differentiation effects of PEMF.
The biological process of osteogenesis is known as bone remodelling. At the cellular level bones are remodelled through an organised process. Osteoclasts remove old bone and osteoblasts replace it with newly formed bone.
A study completely in 2014 treated human mesenchymal stem cells derived from bone marrow and adipose tissue with PEMF therapy. This was done to compare the role of PEMF on different tissues. Osteogenic markets were analysed at different times during and after treatment. The results indicated that PEMF stimulated growth in both bone marrow and adipose tissue. In their conclusion it was stated that PEMF therapy may be a possible tool to improve autologous cell-based regeneration of bone defects in orthopedics.
The research for PEMF therapy and osteoporosis is extensive and well validated. It presents with no side effect profiles and uniform results indicating efficacy. Furthermore the other therapeutic options display low efficacy and large side effect profiles.
Osteoporosis is a major health issue worldwide and with ongoing research into PEMF therapy its therapeutic potential is enormous. Why isn’t this treatment offered in care facilities, hospitals, clinics, retirement complexes, or personal use at home?
PEMF has not (until recently) been considered a mainstream therapeutic option. European nations have been using PEMF therapy since the early 1900s. However as more research and validated devices come onto the market clinical use has bloomed. Today it is easier than ever to receive PEMF treatment or even a personal device.
Jing, D., Li, F., Jiang, M., Cai, J., Wu, Y., Xie, K., … Luo, E. (2013). Pulsed electromagnetic fields improve bone microstructure and strength in ovariectomized rats through a Wnt/Lrp5/??-catenin signaling-associated mechanism. PLoS ONE, 8(11). http://doi.org/10.1371/journal.pone.0079377
Esmail, M. Y., Sun, L., Yu, L., Xu, H., Shi, L., & Zhang, J. (2012). Effects of PEMF and glucocorticoids on proliferation and differentiation of osteoblasts. Electromagnetic Biology and Medicine, 31(4), 375–81. http://doi.org/10.3109/15368378.2012.662196
Tabrah, F., Hoffmeier, M., Gilbert, F., Batkin, S., & Bassett, C. a. (1990). Bone density changes in osteoporosis-prone women exposed to pulsed electromagnetic fields (PEMFs). Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research, 5(5), 437–42. http://doi.org/10.1002/jbmr.5650050504
Wang, Y., & Qin, Q.-H. (2012). A theoretical study of bone remodelling under PEMF at cellular level. Computer Methods in Biomechanics and Biomedical Engineering, 15(8), 885–897. http://doi.org/10.1080/10255842.2011.565752
Chang, K., & Chang, W. H. S. (2003). Pulsed Electromagnetic Fields Prevent Osteoporosis in an Ovariectomized Female Rat Model: A Prostaglandin E2-Associated Process. Bioelectromagnetics, 24(3), 189–198. http://doi.org/10.1002/bem.10078
Ongaro, A., Pellati, A., Bagheri, L., Fortini, C., Setti, S., & De Mattei, M. (2014). Pulsed electromagnetic fields stimulate osteogenic differentiation in human bone marrow and adipose tissue derived mesenchymal stem cells. Bioelectromagnetics, 35(6), 426–436. http://doi.org/10.1002/bem.21862
Yan, J. L., Zhou, J., Ma, H. P., Ma, X. N., Gao, Y. H., Shi, W. G., … Chen, K. M. (2015). Pulsed electromagnetic fields promote osteoblast mineralization and maturation needing the existence of primary cilia. Molecular and Cellular Endocrinology, 404, 132–140. http://doi.org/10.1016/j.mce.2015.01.031
Handoll Helen, H. G., & Elliott, J. (2015). Rehabilitation for distal radial fractures in adults. Cochrane Database of Systematic Reviews, (9). http://doi.org/10.1002/14651858.CD003324.pub3